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Pazopanib: a novel treatment option 
for aggressive fibromatosis
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Abstract 
Background: Aggressive fibromatosis (AF), also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF 
does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well doc-
umented. No effective cytotoxic treatment has been reported, hence there is a need for novel treatment strategies.
Case presentation: We present the case of an AF successfully treated with an oral tyrosine kinase inhibitor, pazo-
panib, with mild side effects. As far as we know, this is the first case of AF with complete response to pazopanib.
Conclusion: Pazopanib might be an effective treatment option for AF.
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Background
Aggressive fibromatosis (AF) (also called deep fibroma-
tosis or desmoid tumor) is a proliferation of cytologically 
benign-appearing fibrocytes, often resulting in significant 
functional loss. The nature of the lesion is controver-
sial: some evidence suggests that it is a reactive process, 
whereas other evidence supports a neoplastic etiology 
[1]. Although it does not have the propensity of distant 
organ metastases, AF often exhibits an infiltrative pat-
tern of spread in an abundant collagen matrix, giving it a 
dense, fibrotic character. As a result, this tumor can pro-
duce local tissue destruction leading to significant mor-
bidity and functional loss.
Since the etiology of AF is poorly understood, several 
medical approaches have been combined with or with-
out surgical resection with scarce results. These include 
chemotherapy with doxorubicin-based combinations, 
antiestrogen therapy with tamoxifen, nonsteroidal anti-
inflammatory drugs (NSAIDs) such as indomethacin 
and sulindac, colchicines [2]. However, all of these treat-
ment approaches show moderate activity. Due to a lack of 
efficacious treatment options, patients might die due to 
local organ dysfunction because of their locally progres-
sive disease.
Sporadic AF is usually associated with somatic muta-
tions in codons 41 or 45 of exon 3 of beta-catenin 
(CTNNB1). AF occurring in the background of familial 
adenomatous polyposis (FAP) usually contains inactivat-
ing germline mutations in the adenomatous polyposis 
coli (APC) gene. CTNNB1 and APC are part of the Wnt 
signaling pathway and mutations in either gene resulting 
in stabilization of the beta-catenin protein and allowing 
nuclear translocation and binding of beta-catenin to the 
T cell factor/lymphoid enhancer factor (TCF/Lef ) family 
of transcription factors, lead to activation of target genes 
that may underlie desmoid tumor biology and clinical 
behavior. In the era of molecularly targeted therapeu-
tics, there is a need to exploit the molecular mechanisms 
behind desmoid tumorigenesis and progression in a bet-
ter way. Recently, new encouraging data with small mol-
ecule tyrosine kinase inhibitors (imatinib, sunitinib etc.,) 
have been published [3–7].
These new data support further investigation of the role 
of novel tyrosine kinases in AF. Pazopanib is one of the 
latest anti-angiogenic drugs developed to target VEGF 
and PDGF. It has recently been approved for the treat-
ment of advanced renal cancer and soft-tissue sarcomas 
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by the US Food and Drug Administration (FDA) and by 
the European Medicines Agency (EMA). [8, 9].
Case report
Here we report a case of AF treated successfully with paz-
opanib. In 2013, a 50-year-old male was admitted to our 
University Hospital with recurrent episodes of abdominal 
pain, and loss of appetite. He did not have any comor-
bid disease and was not on any medication. Computed 
tomography (CT) scan showed an intra-abdominal soft 
tissue mass of 5 × 4 × 3 cm originating from the retrop-
eritoneum. For both diagnostic and therapeutic reasons, 
he underwent a surgical excision of the mass, including 
partial resection of transverse colon. Pathological exami-
nation revealed aggressive fibromatosis with a low prolif-
eration index. The surgical procedure was accepted as R2 
resection of the residual mass.
In spite of the residual mass after surgery, and consid-
ering that the Ki-67 index was 3% and the patient was 
asymptomatic, no further treatment was offered at that 
time. A wait-and-see policy is one of the most acceptable 
options with slowly progressing AFs, since AF can show 
very varying clinical behavior, ranging from spontane-
ous regression to rapid progression leading to local organ 
dysfunction [10].
During his planned follow-up visits, CT scans revealed 
progression of residual mass and tamoxifen 20  mg/daily 
was started. After 3  months on tamoxifen, progressive 
disease was detected by CT scan (Fig.  3a, b). This time, 
the patient complained of abdominal cramps and his 
creatinine level was rising due to invasion of bladder by 
tumoral mass. Since no cytotoxic treatment was reported 
to have an efficacy for AF, we searched for possible treat-
ment options on PubMed. Recently, new data has been 
released to demonstrate the efficacy of tyrosine kinases 
for AF [11]. It was suggested that kinase-targeting therapy 
may be effective against AF as there may be an autocrine/
paracrine loop in AF that sustains platelet-derived growth 
factor receptor (PDGFR)-α and PDGFR-β activation [12]. 
Based on the literature that Pazopanib may be an effective 
treatment option in desmoid tumor/aggressive fibromato-
sis, we decided to treat our patient with pazopanib. The 
schedule was 800 mg/day. He tolerated the drug quite well 
with mild to moderate GI symptoms, including grade I 
diarrhea. One month after the initiation of pazopanib, he 
presented with vitiligo and hair depigmentation (Figs.  1, 
2) which are quite common side effects of pazopanib.
On the follow-up period, first response to treatment 
was documented 4  months after the initiation of treat-
ment (Fig.  3c). The response to treatment lasted on the 
follow-up visits, and after 22  months on pazopanib; 
complete response was achieved on patient’s last scan 
(Fig. 3d).
Conclusion
Our report demonstrates that pazopanib is an effective 
and well-tolerated treatment option for the treatment of 
AF. To the best of our knowledge, this is the first reported 
Fig. 1 The photographs the patient before treatment pazopanib
Fig. 2 One month after the start of pazopanib treatment; Patient 
presented with loss of hair color and vitiligo
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case of AF where a complete response was achieved with 
pazopanib. AF has various clinical presentations, from 
spontaneous regression to rapid progression of tumor, 
necessitating a precise treatment decision. In our case, 
the patient was progressing not only radiologically but 
also clinically, which led us to decide in favor of a tar-
geted treatment for this case.
Angiogenesis is one of the fundamental mechanisms in 
cancer and many studies suggest that it also plays a cru-
cial role in soft tissue sarcomas [13]. Based on the results 
of a phase 3 randomized, placebo-controlled trial pazo-
panib was approved by the FDA in 2012 for the treatment 
of patients with locally advanced or metastatic soft tissue 
sarcoma after treatment with standard chemotherapy [14].
Owing to low or no cumulative toxicity of pazopanib 
compared to standard chemotherapy may allows an 
extended treatment duration. However, this observation 
clearly needs to be confirmed in prospective studies. The 
French Sarcoma Group has conducted a phase II trial 
that assesses the efficacy and toxicity of pazopanib in AF 
(ClinicalTrials.gov identifier NCT01876082). We hope 
that above mentioned clinical trial will confirm the effec-
tiveness of pazopanib in AF, a challenging atypical tumor.
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Fig. 3 Patient CT scans; a before initial treatment of tamoxifen; axial plan CT scan performed in September 2013 demonstrates 2.89 cm diameter 
homogeneous mass located at the left anterior pararenal space of the retroperitoneal area (yellow arrow). b Post contrast CT images in december 
2013; retroperitoneal mass (diameter 4.14 cm) progressed after treatment of tamoxifen (yellow arrow). c 9 months after the initiation of pazopanib 
treatment; the residual mass regressed on CT scan at same level (yellow arrow). d Post contrast CT images obtained in October 2015 showing com-
plete response of the residual mass at 22 months of pazopanib treatment.(yellow arrow)
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